{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:10:55Z","timestamp":1793502655379,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.radonc.2024.110288","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T02:52:52Z","timestamp":1713667972000},"page":"110288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-2966","authenticated-orcid":false,"given":"Emma","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus J.","family":"Killean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain D.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110288_b0005","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0015","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0030","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110288_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110288_b0040","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110288_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0050","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110288_b0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110288_b0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJMe1906363","article-title":"Improving treatment for advanced prostate cancer","volume":"381","author":"Tannock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110288_b0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110288_b0075","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2024.110288_b0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110288_b0085","unstructured":"Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org) [Internet]."},{"key":"10.1016\/j.radonc.2024.110288_b0090","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110288_b0095","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110288_b0100","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2024.110288_b0105","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2024.110288_b0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10585-021-10126-7","article-title":"Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials","volume":"38","author":"Pezzulla","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2024.110288_b0115","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1007\/s00259-021-05298-z","article-title":"Stereotactic radiotherapy to oligoprogressive lesions detected with","volume":"48","author":"Onal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2024.110288_b0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pros.24132","article-title":"Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone\/enzalutamide treatment","volume":"81","author":"Onal","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.radonc.2024.110288_b0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10585-022-10158-7","article-title":"Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection","volume":"39","author":"Franzese","year":"2022","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.radonc.2024.110288_b0135","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s12094-021-02553-5","article-title":"Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy","volume":"23","author":"Ingrosso","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0140","article-title":"Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide","author":"La Vecchia","year":"2022","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2024.110288_b0145","article-title":"Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib","volume":"19","author":"Weiss","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.radonc.2024.110288_b0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0155","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.21037\/tlcr-21-682","article-title":"Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"10.1016\/j.radonc.2024.110288_b0160","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0165","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00432-021-03831-z","article-title":"Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study","volume":"148","author":"Wei","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2018.08.005","article-title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?","volume":"124","author":"Merino Lara","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110288_b0175","article-title":"The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma","author":"Franzese","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0180","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2024.110288_b0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2019.08.018","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter","volume":"142","author":"Thompson","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0195","article-title":"Outcomes of stereotactic body radiotherapy for metastatic colorectal cancer with oligometastases, oligoprogression, or local control of dominant tumors","volume":"10","author":"Ji","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters","volume":"161","author":"Tan","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3389\/fonc.2020.00987","article-title":"Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer","volume":"10","author":"Weykamp","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/0284186X.2022.2063067","article-title":"Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease","volume":"61","author":"Ramadan","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110288_b0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.05.013","article-title":"Combination of SABR With anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma: results of a prospective multicenter observational study","volume":"114","author":"Chicas-Sett","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12032-018-1190-8","article-title":"Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study","volume":"35","author":"Mazzola","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0230","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0235","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s00432-021-03807-z","article-title":"Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production","volume":"147","author":"Franzese","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/ajco.13115","article-title":"Utilization of stereotactic ablative radiotherapy in oligometastatic & oligoprogressive skeletal metastases: Results and pattern of failure","volume":"15","author":"Kam","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0245","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ijrobp.2020.10.004","article-title":"Stereotactic body radiation therapy for mediastinal and hilar lymph node metastases","volume":"109","author":"Shahi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2018.04.022","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0255","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2022.01.019","article-title":"Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study","volume":"168","author":"Willmann","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0260","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0265","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.ijrobp.2008.06.1922","article-title":"Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome\u2013results of a retrospective study","volume":"73","author":"Wiegel","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","article-title":"PSA velocity and doubling time in diagnosis and prognosis of prostate cancer","volume":"5","author":"Vickers","year":"2012","journal-title":"Br J Med Surg Urol"},{"key":"10.1016\/j.radonc.2024.110288_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862995","article-title":"Oligoprogression in metastatic, castrate-resistant prostate cancer-prevalence and current clinical practice","volume":"12","author":"Patel","year":"2022","journal-title":"Front Oncol"},{"issue":"16_suppl","key":"10.1016\/j.radonc.2024.110288_b0280","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0285","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12094-018-02005-7","article-title":"Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer","volume":"21","author":"Desideri","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2018.04.008","article-title":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group","volume":"98","author":"Meyer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110288_b0295","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0300","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ijrobp.2022.08.026","article-title":"Validation of the prognostic utility of ESTRO\/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial","volume":"114","author":"Baker","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0305","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","article-title":"Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110288_b0310","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.radonc.2024.110288_b0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110288_b0320","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ijrobp.2022.08.027","article-title":"Local therapy for oligoprogressive disease: a systematic review of prospective trials","volume":"114","author":"Kim","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110288_b0325","unstructured":"Schellenberg D, Gabos Z, Duimering A, Debenham BJ, Fairchild A, Huang F, et al. Stereotactic ablative radiotherapy for oligo-progressive cancers: results of the randomized phase II STOP trial. Int J Radiat Oncol*Biol*Phys 2023;117(2, Supplement):S58."},{"key":"10.1016\/j.radonc.2024.110288_b0330","doi-asserted-by":"crossref","unstructured":"Rans K, Berghen C, Joniau S, Goffin K, De Roover R, De Meerleer G. Progression-directed therapy in oligoprogressive castration-refractory prostate cancer: results of the prospective single-arm phase II MEDCARE trial. IntJ Radiat Oncol*Biol*Phys 2023;117(2, Supplement):S26-S7.","DOI":"10.1016\/j.ijrobp.2023.06.285"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:11:57Z","timestamp":1731028317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402400210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":66,"alternative-id":["S016781402400210X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110288","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110288"}}